Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 3/20 | 0.41 |
| ▸ | CCNK | O75909 | 2/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21811243 | 1.00 | PAK1 (0.41) | PAK1CCNKCDK12PIK3CDPIK3R1 | |
| SCHEMBL23236320 | 0.85 | EGFR (0.43) | PAK1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL23236321 | 0.85 | EGFR (0.43) | PAK1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL29124357 | 0.84 | PIK3CD (0.53) | PIK3CDPIK3CABTK | |
| SCHEMBL31170908 | 0.84 | PIK3CD (0.53) | PIK3CDPIK3CABTK | |
| SCHEMBL29124358 | 0.84 | PIK3CD (0.53) | PIK3CDPIK3CABTK | |
| SCHEMBL21811035 | 0.82 | PIK3CD (0.43) | PAK1CCNKCDK12PIK3CDPIK3CA | |
| SCHEMBL21811034 | 0.82 | PIK3CD (0.43) | PAK1CCNKCDK12PIK3CDPIK3CA | |
| SCHEMBL21811264 | 0.81 | HSD11B1 (0.51) | PAK1CCNKCDK12PIK3CDPIK3R1 | |
| SCHEMBL21811262 | 0.81 | HSD11B1 (0.51) | PAK1CCNKCDK12PIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206765-A1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-07-08 | — | — | US | disclosed |
| EP-3808747-A1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-04-21 | — | — | EP | disclosed |
| WO-2020054788-A1 | IMIDAZOPYRIDINONE COMPOUND | キッセイ薬品工業株式会社 | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206765-A1 | IMIDAZOPYRIDINONE COMPOUND | DHPS, EGLN3, P4HA1 | PAK1 805/4885CCNK 3942/4885CDK12 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.